HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer

Oral Oncology

Volumn 48, Issue 5, 2012, Pages 409-416

  Wild, Clarissa A ^a   Brandau, Sven ^a   Lotfi, Ramin ^b   Mattheis, Stefan ^a   Gu, Xiang ^a   Lang, Stephan ^a   Bergmann, Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

HMGB1; HNSCC; Immunosuppression; TLR; Treg

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CHEMOTAXIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; LARYNX CARCINOMA; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PHARYNX CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 4;

EID: 84859950996     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.12.009     Document Type: Article

References (39)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357(9255):539-45. (Pubitemid 32173595)
2. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24(1):95-105. (Pubitemid 40576066)
3. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4(8):641-8. (Pubitemid 39025049)
4. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5(4):331-42. (Pubitemid 40516158)
5. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006;176(1):12-5. (Pubitemid 43023243)
6. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88.
7. Gokhale AS, McLaughlin BT, Flickinger JC, Beriwal S, Heron DE, Ferris RL, et al. Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. Ann Oncol 21(1):145-51.
8. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13(10):2836-48. (Pubitemid 46850704)
9. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 2003;63(9):2188-93. (Pubitemid 36538625)
10. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003;10(2):445-8.
11. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008;216(2):167-75.
12. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003;10(6):1863-8.
13. Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009;103(12):1949-53.
14. Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P, et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 2010;46(16):3007-15.
15. Choi J, Lee MK, Oh KH, Kim YS, Choi HY, Baek SK, et al. Interaction effect between the receptor for advanced glycation end products (RAGE) and highmobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 2011;97(2):196-202.
16. Wild CA, Brandau S, Lindemann M, Lotfi R, Hoffmann TK, Lang S, et al. Toll-like receptors in regulatory T Cells of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2010;136(12):1253-9.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25(4):402-8. (Pubitemid 34164012)
18. + Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121(11):2473-83.
19. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203(7):1693-700. (Pubitemid 44036275)
20. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004;164(3):441-9. (Pubitemid 38174771)
21. + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13(15 Pt 1):4345-54.
22. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003;104(6):722-7. (Pubitemid 36418509)
23. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8(7):523-32.
24. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008;20(5):518-23.
25. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009;11(7):615-28.
26. Tang D, Kang R, Zeh 3rd HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010;1799(1-2):131-40.
27. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 31(3):334-41.
28. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010;29(38):5299-310.
29. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004;255(3):332-43. (Pubitemid 38315274)
30. Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta 2008;1783(2):297-311.
31. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 2007;179(1):33-40. (Pubitemid 47606681)
32. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8(1):59-73.
33. Liu Z, Falo Jr LD, You Z. Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T celldependent antitumor immunity. J Immunol 2011;187(1):118-25.
34. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk- Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69(7):3105-13.
35. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13(9):1050-9. (Pubitemid 47517504)
36. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205(2):275-85. (Pubitemid 351281593)
37. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006;116(7):2022-32.
38. Crellin NK, Garcia RV, Hadisfar O, Allan SE, Steiner TS, Levings MK. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 2005;175(12):8051-9. (Pubitemid 41798367)
39. Wang RF. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res 2006;66(10):4987-90.